Fundz

Kayo Thera, Inc. reported raising $750,000 in an initial SEC Form D filing, from an offering of $750,000

PRIVATEJun 05, 2019

Amount Raised

$750,000

$750,000 sold, per SEC Form D (first sale Jun 5, 2019)

Round Type

Seed

PrincetonOtherBiotechnologyHealth CareTherapeutics

Quick answer

KayoThera, Inc. raised $750,000 in a Seed round, dated June 5, 2019. KayoThera, Inc. is based in Princeton, West Virginia, United States.

How much did KayoThera, Inc. raise?
KayoThera, Inc. raised $750,000 in a Seed round on June 5, 2019.
What does KayoThera, Inc. do?
KayoThera, Inc. is an early-stage therapeutics company focused on the development of first-in-class, oral, small molecule inhibitors of the retinoid pathway.
Where is KayoThera, Inc. based and how big is it?
KayoThera, Inc. is based in Princeton, West Virginia, United States.
Who are the decision-makers at KayoThera, Inc?
Fundz holds 1 contact at KayoThera, Inc., including the Executive Officer. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as KayoThera, Inc. that raised within 45 days of this round, from Fundz verified event records.

Who to call at KayoThera, Inc., and when

A new round usually means KayoThera, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day KayoThera, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at KayoThera, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at KayoThera, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

KayoThera, Inc.

Location

155 VILLAGE BLVD., SUITE 130

Princeton, West Virginia, United States

About

KayoThera, Inc. is an early-stage therapeutics company focused on the development of first-in-class, oral, small molecule inhibitors of the retinoid pathway. This pathway plays a critical role in a variety of serious diseases, including cardiometabolic diseases and cancer. KayoThera is developing therapies to treat diabetes and late-stage and metastatic cancers including breast, lung, pancreatic, colorectal, brain, and kidney cancers. The company was founded based on discoveries from Dr. Mark Esposito’s post-doctoral research at Princeton University and professor Yibin Kang, Ph.D. For more information, visit www.kayothera.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment KayoThera, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsSUZANNE R., Executive Officer hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for KayoThera, Inc.'s next move

See what Strategic adds

KayoThera, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.